NCT00889889 - Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination | Biotech Hunter

Enrollment

1,270

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Influenza

Interventions

BIOLOGICAL

Cell-Derived Trivalent Subunit Influenza Vaccine

surface antigen, inactivated, prepared in cell cultures

BIOLOGICAL

Placebo

Trial Locations (15)

27612

Site Reference ID/Investigator# 45688, Raleigh

32216

Site Reference ID/Investigator# 45690, Jacksonville

33024

Site Reference ID/Investigator# 45687, Pembroke Pines

33143

Site Reference ID/Investigator# 45697, South Miami

37203

Site Reference ID/Investigator# 45696, Nashville

40509

Site Reference ID/Investigator# 45682, Lexington

64114

Site Reference ID/Investigator# 45684, Kansas City

66212

Site Reference ID/Investigator# 45689, Overland Park

66219

Site Reference ID/Investigator# 45691, Lenexa

67207

Site Reference ID/Investigator# 45694, Wichita

68134

Site Reference ID/Investigator# 45685, Omaha

76135

Site Reference ID/Investigator# 45695, Fort Worth

78705

Site Reference ID/Investigator# 45683, Austin

84124

Site Reference ID/Investigator# 45692, Salt Lake City

89104

Site Reference ID/Investigator# 45686, Las Vegas